Search Results
Jul 23, 2026, 06:45 ET Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
retatrutide 4 mg, 9 mg, 12 mg, or placebo. Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a stepwise approach every four weeks until reaching the target dose of 4 mg (via steps at 2 mg and 4 mg), 9 mg (via steps at 2 mg, 4 mg, and 6 mg) or 12 mg (via
More news about: Eli Lilly and Company
Jul 22, 2026, 20:06 ET Ribo veröffentlicht positive Daten aus der Phase-2a-Studie zu Vortosiran - weltweit erste klinische Daten zur siRNA-vermittelten FXI-Hemmung nach wiederholter Verabreichung bei Patienten mit koronarer Herzkrankheit
Myokardinfarkt untersucht, die Aspirin einnahmen. Patienten, die das Vortosiran-Behandlungsschema der Hochdosisgruppe mit einer Erhaltungsdosis von 400 mg absolvierten, erreichten eine mittlere maximale Senkung der FXI-Aktivität um 92 %, die über mehrere Monate nach der Verabreichung anhielt. Diese Daten
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 22, 2026, 10:11 ET Ribo revela datos positivos del ensayo de fase 2a de vortosiran
que recibían aspirina. Los pacientes que completaron el régimen de dosificación de vortosiran en dosis altas, con una dosis de mantenimiento de 400 mg, lograron una reducción máxima media de la actividad de FXI del 92 %, que se mantuvo durante varios meses después de la administración. Estos datos respaldan
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 22, 2026, 10:07 ET ERAS Deadline Alert: Levi & Korsinsky Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
Erasca of making "deceptive and untrue comparative statements" and alleged trade secret misappropriationA patient receiving 24 mg of ERAS-0015 experienced a Grade 3 treatment-related adverse event of pneumonitis that progressed to Grade 5 (death), which was not disclosed until after
More news about: Levi & Korsinsky, LLP
Jul 22, 2026, 08:30 ET Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
infarction on aspirin were investigated in the current trial. Patients completing the high dose group vortosiran dosing regimen, at a maintenance dose of 400mg, achieved a mean maximum reduction in FXI activity of 92%, which sustained for several months following dosing. This data supports every three to six
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 22, 2026, 08:22 ET Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
infarction on aspirin were investigated in the current trial. Patients completing the high dose group vortosiran dosing regimen, at a maintenance dose of 400mg, achieved a mean maximum reduction in FXI activity of 92%, which sustained for several months following dosing. This data supports every three to six
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 22, 2026, 08:00 ET Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
tophaceous gout in people with chronic or undertreated disease. Despite available therapies that aim to reduce uric acid levels below the target 6 mg/dL, a major treatment gap remains between first-line xanthine oxidase inhibitors and last-line uricase therapy. Currently, no suitable second-line options
More news about: Crystalys Therapeutics
Jul 22, 2026, 08:00 ET Kirin Group and Blackmores to Launch New Cognizin® Cognitive Support Supplements in Australia and New Zealand
Ultra Brain Care are dietary supplements containing Cognizin® Citicoline, a branded citicoline ingredient from Kyowa Hakko Bio. Each tablet contains 250 mg of Cognizin® Citicoline, with a recommended daily intake of two tablets per day, or as directed by a healthcare professional.The products are
More news about: Kyowa Hakko U.S.A
Jul 22, 2026, 07:00 ET TopGum Advances Longevity with Gummies for Cognition and Vision
Each 3g cherry flavored gummy combines a blend of natural nootropics and adaptogenics. It includes 100mg lion's mushroom extract, hailed for its benefits on immunity and neuroprotective properties; 75mg Brahmi, prized in Ayurvedic medicine as a brain tonic; gotu kola extract, used to reduce anxiety and
More news about: TopGum Industries, Inc.
Jul 21, 2026, 12:47 ET First Cholesterol Guidelines Update Since 2018: Check Earlier, Treat Sooner, and Aim Lower
other risk factors, like those who have diabetes or smoke. The new target LDL is 55 mg/dL, or lower. Previously, the target was 70 mg/dL or lower. The target LDL level for adults who are not at-risk should be 100 mg/dL, or below, said Ambrosy, citing the new guidelines."A target
More news about: Andrew P. Ambrosy, MD, MPH
Jul 21, 2026, 10:54 ET Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
demonstrated durable efficacy, with a mean ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline 12 months after two 16 mg doses administered three weeks apart, and 100% response and 71% remission rates based on a MADRS benchmark of ≤10, with remission rising to 100% using
More news about: Helus Pharma
Jul 21, 2026, 08:30 ET Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
demonstrated durable efficacy, with a mean ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline 12 months after two 16 mg doses administered three weeks apart, and 100% response and 71% remission rates based on a MADRS benchmark of ≤10, with remission rising to 100% using
More news about: Market News Updates
Jul 21, 2026, 07:00 ET Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
demonstrated a mean serum phosphate reduction from baseline of 2.51 mg/dL, compared with 1.08 mg/dL for the active comparator sevelamer carbonate. At Weeks 7 to 8, nearly 95% of patients in the AP306 group had serum phosphate levels below 5.5 mg/dL, compared with approximately 50% in the sevelamer carbonate group
More news about: Alebund Pharmaceuticals
Jul 20, 2026, 13:17 ET Bayer reúne cadeia da cotonicultura em Sorriso para apresentar o futuro da biotecnologia Bollgard no Brasil
a agenda da Bayer em Sorriso será levado ao 15º Congresso Brasileiro do Algodão (CBA), que será realizado de 22 a 24 de setembro, em Belo Horizonte (MG), e reunirá toda a cadeia para a troca de informações e a apresentação de novas tecnologias para o setor.Sobre a BayerGuiada por
More news about: Bayer
Jul 20, 2026, 10:00 ET Akagera Medicines Reports Positive First-in-Human Data for Single-Ascending-Dose of AKG-100, Advancing a Potentially Transformative Long-Acting Therapeutic for Drug-Resistant Tuberculosis
in a 14-day Early Bactericidal Activity (EBA) cohort. AKG-100 was well tolerated at every dose studied, up to and including the highest dose of 850 mg. The overall safety profile was favorable; no participants discontinued due to adverse events and most adverse events were mild and self-limiting.AKG-100
More news about: Akagera Medicines Inc
Jul 20, 2026, 08:34 ET ayrloom, New York's #1 Adult-Use Cannabis Brand With Category Leadership Across Beverages, All-In-One (AIO) Vapes, Tinctures and Topicals, Sees Tremendous Growth Across the Business From 600 Licensed Dispensary Doors Secured (Up 350 From Last Year), to Over 5M Units Sold With 85% YoY Growth
hemp-derived THC beverage brand at leading music festival, Governors Ball.Throughout the three-day festival, over 1,000 3 oz samples of ayrloom's 1mg micro beverages were distributed during "flower hour" each day in addition to over 3,000 cans distributed via concessions + the brand's own activation
More news about: ayrloom
Jul 20, 2026, 05:00 ET Omega-3 Market worth $8.73 billion by 2031- Exclusive Report by MarketsandMarkets™
mandate that all infant formula and follow-on formula available for purchase within the EU must contain a minimum of 20 mg/100 kcal (or 4.8 mg/100 kJ) and a maximum of 50 mg/100 kcal (or 128 mg/100 kJ) of DHA, which is accelerating market growth. In addition, growing consumer preference for organic and clean-label
More news about: MarketsandMarkets
Jul 18, 2026, 14:55 ET REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
com 1Singer MA, et al. Ophthalmology. 2012;119(6):1175-83. 2 Silva R, et al. Ophthalmology. 2012;120,130-39.; 3Maguire MG, et al. Ophthalmology. 2016;123, 1751-61. 4Khanani A, et al. Ophthalmology. 2019;4(2):122-33. 5Ciulla T, et al. Ophthalmology.
More news about: REGENXBIO Inc.
Jul 17, 2026, 08:50 ET Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
randomized 36 patients 2-to-1 active to placebo at 20 mg or 2 mg, given as two intramuscular doses three weeks apart. Patients entered with an average baseline HAM-A of 22 and remained symptomatic despite ongoing standard-of-care antidepressant therapy. The 20 mg dose produced an average improvement of more than
More news about: USA News Group
Jul 17, 2026, 07:00 ET DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
received the drug candidate. The trial successfully demonstrated DMX-652 was safe and well tolerated in single doses of up to 200mg a day and multiple doses of up to 100mg a day for 14 days, with a promising pharmacokinetic profile.Building a focused, rare kidney disease portfolioThe
More news about: Dimerix Limited
Jul 16, 2026, 10:01 ET NASH Treatment Market Accelerates as Rezdiffra and Wegovy Establish Fibrosis-Defined Drug Pathways, Says Strategic Market Research
2 SYNERGY-NASH study, MASH resolution without worsening fibrosis occurred in 44%, 56%, and 62% of patients receiving tirzepatide doses of 5 mg, 10 mg, and 15 mg, respectively, compared with 10% receiving placebo.Akero Therapeutics is advancing efruxifermin through Phase 3 studies for noncirrhotic
More news about: Strategic Market Research LLP
Jul 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
after market hours on April 27, 2026, Erasca reported preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a "Grade 3 TRAE of pneumonitis" that "progressed
More news about: Pomerantz LLP
Jul 16, 2026, 05:00 ET BrainMD Launches Happy Saffron Plus® Gummies, Making Its Beloved Brain Health Formula Easier Than Ever To Enjoy Daily
formula:affron® Saffron Extract A clinically studied saffron extract shown to support positive mood and emotional wellness. Each serving delivers 28 mg of affron®, the same dose used in clinical research.*Longvida® Optimized Curcumin A patented form of curcumin developed for enhanced
More news about: BrainMD
Jul 15, 2026, 20:00 ET ERAS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Erasca Class Action Lawsuit
after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015
More news about: Robbins Geller Rudman & Dowd LLP
Jul 15, 2026, 15:37 ET The Commander-in-Chief of the Military Order of the World Wars, Lt Col David J. Worley, USAF (Retired), will present the Distinguished Service Award to Major General Patrick Henry Brady, United States Army (Retired)
Army veteran who was awarded the Medal of Honor for a series of extraordinary helicopter rescue missions during the Vietnam War. On that fateful day, MG Brady utilized three different helicopters to evacuate 51 critically wounded soldiers from multiple enemy-engaged ("hot") landing zones and a minefield.
More news about: The Military Order of the World Wars